linjc16/ctgov huggingface dataset:
COACH-Cog Intervention Adaptation Focus Groups

Study Overview
=================
Brief Summary
-----------------
To gather key stakeholder input for feedback on the adaption of the COACH GA intervention (i.e., develop COACH-Cog) to enhance triadic communication among oncologists, care partners and patients with ADRD.

Official Title
-----------------
Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision - Focus Groups

Conditions
-----------------
Focus Groups

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion/Exclusion Criteria: The inclusion and exclusion criteria for participants are that they must be able to consent for themselves and must speak English. For the medical oncologist focus group, participants must be a medical oncologist. For the clinicians with expertise in cognitive impairment and dementia focus group, participants must be a clinician that treats patients with cognitive impairment and dementia. For the older patients with cancer focus group, participants must be older than 65 years of age and have or had cancer. For the caregivers of patients with dementia focus group, participants must be caregivers of patients with dementia or cognitive impairment.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical Oncologists<br>Individuals practicing as medical oncologists or with expertise in medical oncology | |
| Clinicians with expertise in cognitive impairment and dementia<br>Clinicians with expertise in cognitive impairment and dementia | |
| Older patients with cancer<br>Older patients with cancer or older survivors of patients with cancer | |
| Caregivers of patients with dementia or cognitive impairment<br>Caregivers of patients with dementia or cognitive impairment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative analysis of focus group audio-recording transcripts. Open coding using content analysis framework will be utilized to assess themes of potential intervention adaptations. | Qualitative data gathered from participants during focus group participation. Focus groups will be audio-recorded and transcribed. Transcribed audio-recordings will be qualitatively analyzed for opportunities and recommendations for further intervention adaptation. Open coding using content analysis framework will be utilized for qualitative analysis. | Through study completion - Focus group participation will be a single, one-time episode. Estimated time from consent to participation in focus groups is 3 months or less. |
Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

Study Overview
=================
Brief Summary
-----------------
In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.

Official Title
-----------------
Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

Conditions
-----------------
Metastasis of Unknown Origin

Intervention / Treatment
-----------------
* Diagnostic Test: PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female. Exclusion Criteria: Patients with known primary tumor Pregnancy. Age < 18 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET/CT|detection of possible primary tumor|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| primary tumor for metastasis of unknown origin | primary tumor for metastasis of unknown origin | one month |
The Relationship Between Covid-19 and Pneumothorax in Patients Hospitalized With Covid-19 During the Pandemic

Study Overview
=================
Brief Summary
-----------------
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax.

Detailed Description
-----------------
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax. The files of covid-19 patients with pneumothorax were reviewed retrospectively. The radiological records and treatment protocols of the patients were reviewed. The results were evaluated in terms of its relationship with pneumothorax.

Official Title
-----------------
The Relationship Between Covid-19 and Pneumothorax in Patients Hospitalized With Covid-19 During the Pandemic

Conditions
-----------------
COVID-19, Pneumothorax

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18 years covid-19 patient having a diagnosis of pneumothorax PCR test positive and lung tomography pneumonic involvement Exclusion Criteria: PCR test negative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relationship between covid-19 and pneumothorax | Inflammatory markers, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, procalcitonin, blood gas lactate, creatine kinase, white blood cells, baseline laboratory test results including WBC, lymphocyte, neutrophil counts, platelets, urea, creatinine, and neutrophil/lymphocyte ratio were documented for each patient. Respiratory support status, the fraction of inspired oxygen (FiO2), positive end-expiratory pressure (PEEP) values, tidal volume, and duration of the mechanical ventilator (MV) stay were determined. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, pneumothorax
The Doppler Feasibility Study

Study Overview
=================
Brief Summary
-----------------
The study is an exploratory research study looking at the feasibility, acceptability and accuracy of a doppler device compared with the gold standard ECG. It will take place in the sleep unit at Sheffield Children's Hospital.

Official Title
-----------------
Feasibility Study to Evaluate a New Hands-free Doppler Heart Rate Monitor Normally Used to Measure the Fetal Heart Rate

Conditions
-----------------
Heart Rate Measurements

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been referred for a cardio-respiratory polygraphy sleep study. Patients aged one month up to one year old. Exclusion Criteria: Subjects whose parents/legal guardians/carers are not fluent in English, or who have special communication needs. Child anticipated to become distressed with additional sensor. Child too clinically unwell to take part (as decided by clinical staff).

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Comparison<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of the system in 15 patients, when compared with the gold standard ECG |  | 1 hour | 
| The acceptability of the sensor to the child as viewed by the parent | As measured by researcher designed questionnaire | 1 hour |
Challenges in Management of Abdominal Trauma in Sohag University Hospital A Prospective Study

Study Overview
=================
Brief Summary
-----------------
The present study will be conducted to evaluate the different patterns of abdominal trauma patients and their management in the Emergency Department of Sohag University Hospital

Detailed Description
-----------------
The present study will be conducted to evaluate the different patterns of abdominal trauma patients and their management in the Emergency Department of Sohag University Hospital This study will be a prospective study which will be conducted at the Emergency Department of Sohag University Hospital the study population include all patients with abdominal trauma

Official Title
-----------------
Challenges in Management of Abdominal Trauma in Sohag University Hospital A Prospective Study

Conditions
-----------------
Abdominal Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient presented with abdominal trauma Exclusion Criteria: Patients with extra abdominal injuries
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with surgical intervention<br> | |
| patients with no surgical intervention<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality at final follow up |  | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morbidity |  | one month |
Pentosan Polysulfate Treatment's Effectiveness

Study Overview
=================
Brief Summary
-----------------
To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).

Detailed Description
-----------------
Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.

Official Title
-----------------
Retrospective Evaluation of the Effectiveness of Oral Pentosan Polysulfate Treatment in the Improvement of Chronic Interstitial Cystitis Symptoms.

Conditions
-----------------
Chronic Interstitial Cystitis

Intervention / Treatment
-----------------
* Other: Pentosan Polysulphate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic interstitial cystitis Bladder Pain Syndrome Exclusion Criteria: Acute cystitis Bladder cancer Chronic prostatitis Bladder stone Stress incontinence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: two models: with and without Hunner's ulcer
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: With Hunner's ulcer<br>Pentosan Polysulfate 100 mg | Other: Pentosan Polysulphate<br>* 300mg 3 times a day<br>|
| Active Comparator: Without Hunner's ulcer<br>Pentosan Polysulfate 100 mg | Other: Pentosan Polysulphate<br>* 300mg 3 times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bladder wall thickness | 0.3 over 3 mm 1 under 3 mm, | Three months | 
| improvement of lower urinary tract symptoms | 1 if symptoms improved, 0 if not | Three months |
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Study Overview
=================
Brief Summary
-----------------
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept

Official Title
-----------------
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)

Conditions
-----------------
Diabetic Macular Edema

Intervention / Treatment
-----------------
* Drug: EYP-1901
* Drug: Aflibercept 2Mg/0.05Ml Inj,Oph


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit. BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1). Exclusion Criteria: Any current or history of ocular disease other than DME BCVA using ETDRS charts <30 letters (20/250 Snellen equivalent) in the fellow eye. Active ocular inflammation or active infection in either eye at Baseline (Day 1).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EYP-1901 1343 µg<br>EYP-1901 1343 µg, single dose | Drug: EYP-1901<br>* Intravitreal Injection<br>|
| Experimental: EYP-1901 2686 µg<br>EYP-1901 2686 µg, single dose | Drug: EYP-1901<br>* Intravitreal Injection<br>|
| Active Comparator: Aflibercept<br>Aflibercept 2 mg/0.05mL solution, single dose | Drug: Aflibercept 2Mg/0.05Ml Inj,Oph<br>* Intravitreal Injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept |  | Week 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in best corrected visual acuity (BCVA) |  | Week 24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DME, EYP-1901, EyePoint
Effect of Smartphone Addiction on Myoelectrical Activity of Sternocleidomastoid Muscle in Adult

Study Overview
=================
Brief Summary
-----------------
This study will be conducted to identify the effect of smartphone addiction myoelectrical activity on sternocleidomastoid in adults by measuring The amplitude of EMG signals of the sternocleidomastoid muscle in adults and Root mean square of EMG signals of the sternocleidomastoid muscle in adults

Official Title
-----------------
Effect of Smartphone Addiction on the Myoelectrical Activity of the Sternocleidomastoid Muscle in Adult

Conditions
-----------------
Heavy Smart Phone Users

Intervention / Treatment
-----------------
* Device: EMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject's age range from 18-30 years old All participants use the same smartphone with a touch screen of 6,7 inches. Exclusion Criteria: Neck pain ( spondylosis, spondylolysis) Systemic diseases. Spinal deviation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| smart phone addict<br> | Device: EMG<br>* Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.<br>|
| smart phone non addict<br> | Device: EMG<br>* Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in surface electromyographic (EMG) amplitude of sternocleidomastoid muscle | change in amplitude measured by EMG device | day 1 | 
| change in RMS | change in root mean square measured by EMG device | day 1 |
Screening of Subclinical Hypothyroidism in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
this study may help the physicians to evaluate the practice of universal screening of sub-clinical hypothyroidism and thyroid-stimulating hormone level. Detection of sub-clinical hypothyroidism early in pregnancy through thyroid-stimulating hormone sampling in the first trimester will allow achieving proper management and better maternal and neonatal outcome of these patients.

Detailed Description
-----------------
This is a cross-sectional study will be carried out on women attending Obstetrics Outpatient Clinic in Sohag University Hospitals between April and 1st December 2023 for the booking antenatal care visit and to be invited to enroll in the study. The attending physician will explain the nature of the study to the cases, the blood samples will be collected and to be assessed for the routine antenatal screening complete blood count, random blood sugar, hepatitis B virus and HIV, the same blood sample will be used to asses TSH level.

Official Title
-----------------
Prevalence of Sub-clinical Hypothyroidism Among Pregnant Women During First Trimester: Cross Sectional Study.

Conditions
-----------------
Subclinical Hypothyroidism

Intervention / Treatment
-----------------
* Diagnostic Test: serum T.S.H level test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age group 18 years to 45 years. first trimester pregnant women. Exclusion Criteria: Women with known thyroid disorders or previous thyroidectomy. Pregnant women with hyperemesis gravidarum. Molar pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnosis of subclinical hypothyroidism early in pregnancy | by serum TSH level | in the first trimester of pregnancy ( first 12 weeks) |
Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the number of patients with elevated blood tryptase for whom this elevation could be linked to a hereditary alpha-tryptase secretion abnormality or hyper-alpha-tryptasemia. This information will enable to better optimize the management and follow-up of patients who have experienced hypersensitivity reactions and have elevated basal blood tryptase levels. The patients will be offered the opportunity to take part in the study. If they consent to participate, they will be tested for hereditary hyper-alpha-tryptasemia. A blood sampling will be performed in the center. A few weeks after, the patient will be informed about the blood sample result during a medical consultation organized in the center.

Official Title
-----------------
Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia (Protocol HaT)

Conditions
-----------------
Allergic Bronchiolitis

Intervention / Treatment
-----------------
* Genetic: Serum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who came in the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup Patients who have received at least one basal tryptase assay, according to recommendations informed consent signature Exclusion Criteria: High tryptasemia (≥ 8ng/ml) synchronous with anaphylactic reaction and unconfirmed basally Known diagnosis of systemic mastocytosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Samples Without DNA<br>Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history). | Genetic: Serum<br>* Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of hereditary hyper alpha-tryptasemia | Analysis machine by PCR | at inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phenotyping our patient cohort | longitudinal follow-up of clinical symptoms according to patient subgroups in relation to mast cell pathologies. | at 36 months | 
| Set up a serotheque to support scientific and medical projects in this field | Biobanking | At inclusion |